J&J's Unbroken Payout Streak: A Dividend Investor's Dream
Johnson & Johnson is an attractive dividend stock for long-term investors due to its consistent payout history and diversified business.
The company has raised its dividend annually for 64 consecutive years, making it a Dividend King. In April 2026, the board lifted the quarterly per-share dividend from $1.30 to $1.34, a 3.1% increase, and reaffirmed the payout again in July for the third quarter.
The annual dividend now sits around $5.36 per share, with a yield near 2% at current prices. Total shareholder yield looks higher once you factor in buybacks.
Johnson & Johnson's business is diversified across two main segments: Innovative Medicine and MedTech. The pharma side works in oncology, immunology, neuroscience, and cardiopulmonary diseases, selling branded medicines through hospitals and doctors who treat cancer, autoimmune conditions, and mood disorders. The MedTech side builds devices and surgical tools used in cardiovascular care, orthopedics, operating rooms, and vision care.
The company's diversified business reduces reliance on any single product or platform, with 28 drug or product platforms generating at least $1 billion of annual revenue.